Compare KNRX & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNRX | ICCM |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Singapore | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 41.4M |
| IPO Year | N/A | 2013 |
| Metric | KNRX | ICCM |
|---|---|---|
| Price | $1.26 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 58.7K | ★ 739.3K |
| Earning Date | 06-12-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $139.51 |
| Revenue Next Year | N/A | $75.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.28 |
| 52 Week High | $3.45 | $1.40 |
| Indicator | KNRX | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 36.92 |
| Support Level | $0.83 | $0.28 |
| Resistance Level | $1.45 | $0.74 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 14.81 | 73.42 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.